Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the stocks Jim Cramer recently looked at. When a caller noted that they bought the stock three years ago for around $12, Cramer remarked:
“Congratulations. You know that one’s done. They got that nice bid from Sanofi. I’m going to actually go out there and talk to them about that… Well played, my friend.”
Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels
Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that creates and sells advanced vaccines, including a specialized shot for hepatitis B and a unique additive used to boost immune responses. On December 24, Sanofi (NASDAQ:SNY) announced that it is acquiring the company for nearly $2.2 billion. The deal involves a cash tender offer of $15.50 per share. The CEO of Dynavax Technologies Corporation (NASDAQ:DVAX), Ryan Spencer, commented:
“We believe Sanofi’s commercial reach, development capabilities and commitment to evidence-based immunization will amplify the opportunity for HEPLISAV-B and our innovative pipeline to address important public health needs, further advancing our mission to help protect the world against infectious disease. We are confident that this transaction – and the compelling value it provides – is in the best interests of the Company and its stockholders.”
While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
